Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als
Patent No. EP1714960 (titled "Novel Therapeutic Agent For Amyotrophic Lateral Sclerosis (Als) Or Disease Attributable To Als") was filed by Mitsubishi Pharma on Feb 9, 2005. The application was issued on Mar 28, 2018.
Patent Summary
3-Methyl-1-phenyl-2-pyrazoline-5-on (edaravone), including its physiologically acceptable salts, hydrates, or solvates, is used to treat amyotrophic lateral sclerosis (ALS), manage ALS-related symptoms, or suppress disease progression, such as respiratory function decline. The therapeutic regimen is characterized by the inclusion of at least one drug holiday period—defined as a period without drug administration—occurring once, twice, or more during the treatment course. Specifically, the administration is structured such that both the drug administration period and the drug holiday period each last 14 days. This intermittent dosing strategy aims to provide therapeutic efficacy, including suppressing the decrease in ALSFRS-R scores, while minimizing adverse effects compared to continuous administration.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
EP1714960
- Application Number
- EP05709984A
- Filing Date
- Feb 9, 2005
- Status
- Revoked
- Aug 21, 2020
- Publication Date
- Mar 28, 2018
- External Links
- Slate, Register , Google Patents